儿童活衰减奇孔古尼亚疫苗:一个随机的第二阶段试验
Petronela Weisová1, Susanne Scheiblauer2, Jacqueline Ecker2
1Valneva Austria GmbH, Vienna, Austria. Petronela.WEISOVA@valneva.com.
Nature medicine
|February 6, 2026
概括
一种活减弱的奇孔古尼亚病毒 (CHIKV) 疫苗 (VLA1553) 在1-11岁儿童中表现出良好的耐受性和安全性. 全剂量VLA1553引起了更高的抗体反应,支持其用于儿科CHIKV预防的进展.
科学领域:
- 病毒学和疫苗学.
- 儿童传染病 儿童传染病
- 临床试验和流行病学
背景情况:
- 奇孔古尼亚病毒 (CHIKV) 构成重大威胁,目前没有针对12岁以下儿童的授权疫苗.
- 这一年龄组在流行地区特别脆弱,突显了急需儿童CHIKV预防策略的迫切需要.
研究的目的:
- 评估1至11岁的健康儿童中活体减弱CHIKV疫苗候选人VLA1553的耐受性,安全性和免疫性.
- 为了确定未来儿科临床试验中VLA1553的最佳剂量 (一半或全剂量).
主要方法:
- 第二阶段,观察者盲,随机化,剂量反应试验,涉及304名1至11岁的健康儿童,来自CHIKV流行国家.
- 参与者接受了VLA1553的半剂量或全剂量,或者接受了活性对照剂 (脑膜炎球菌疫苗).
- 安全性通过被要求和不受要求的不良事件 (AE) 进行评估,而免疫性则通过抗CHIKV中和抗体标位测量,直到接种疫苗后28天.
主要成果:
- 在所有年龄组 (1-2,3-6岁和7-11岁) 中,VLA1553与对照疫苗具有可比的耐受性和安全性.
- 常见的应急副作用包括注射部位的疼痛/疼痛以及发烧和头痛等全身性事件.
- 与14日和28日半剂量组相比,VLA1553全剂量组的抗CHIKV中和抗体标位显著更高.
结论:
- 活体减弱CHIKV疫苗候选人VLA1553在1至11岁儿童中耐受性良好且安全.
- 全剂量VLA1553显示出优异的免疫性,支持其选择进一步临床开发.
- 这些发现解决了儿童奇孔古尼亚预防的严重未满足的医疗需求.
相关概念视频
Vaccinations
51.8K
Overview
51.8K
Transcription Attenuation in Prokaryotes
18.5K
Transcriptional attenuation occurs when RNA transcription is prematurely terminated due to the formation of a terminator mRNA hairpin structure. Bacteria use these hairpins to regulate the transcription process and control the synthesis of several amino acids including histidine, lysine, threonine, and phenylalanine. Transcription attenuation takes place in the non-coding regions of mRNA.
There are several different mechanisms used to attenuate transcription. In ribosome mediated...
There are several different mechanisms used to attenuate transcription. In ribosome mediated...
18.5K
Clinical Trials: Overview
5.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.0K
Trial and Error and Algorithm
425
A problem-solving strategy is a plan of action used to find a solution. Different strategies have distinct action plans. Trial and error involves trying different solutions until one works. For instance, to fix a broken printer, you might check ink levels, ensure the paper tray isn't jammed, and verify the printer's connection to your laptop. This method can be time-consuming but is commonly used. Thomas Edison, for example, used trial and error to find a suitable filament for the light...
425
Clinical Trials
10.8K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.8K
Random Error
9.8K
Random or indeterminate errors originate from various uncontrollable variables, such as variations in environmental conditions, instrument imperfections, or the inherent variability of the phenomena being measured. Usually, these errors cannot be predicted, estimated, or characterized because their direction and magnitude often vary in magnitude and direction even during consecutive measurements. As a result, they are difficult to eliminate. However, the aggregate effect of these errors can be...
9.8K


